A new lead to NLRP3 inhibition

Mohamed Lamkanfi; Vishva M Dixit

doi:10.1084/jem.20171848

A new lead to NLRP3 inhibition

J Exp Med. 2017 Nov 6;214(11):3147-3149. doi: 10.1084/jem.20171848. Epub 2017 Oct 23.

Authors

Mohamed Lamkanfi¹, Vishva M Dixit²

Affiliations

¹ VIB-UGent Center for Inflammation Research, VIB; and Department of Internal Medicine, Ghent University, Ghent, Belgium; Department of Physiological Chemistry, Genentech, South San Francisco, CA.
² VIB-UGent Center for Inflammation Research, VIB; and Department of Internal Medicine, Ghent University, Ghent, Belgium; Department of Physiological Chemistry, Genentech, South San Francisco, CA mohamed.lamkanfi@irc.vib-ugent.be Dixit.vishva@gene.com.

Abstract

The discovery of a small molecule inhibitor that targets the inflammasome sensor NLRP3 offers a new path for the development of selective inflammasome blockers with potential therapeutic benefit in a wide range of human diseases (in this issue, see Jiang et al., https://doi.org/10.1084/jem.20171419).

Publication types

Comment

MeSH terms

Humans
Inflammasomes*
NLR Family, Pyrin Domain-Containing 3 Protein

Substances

Inflammasomes
NLR Family, Pyrin Domain-Containing 3 Protein
NLRP3 protein, human